Study of the Expression Levels of Survivin Gene in Patients with Acute Myeloid Leukemia

Authors

  • Hadeer Aly Abbassy M.D. Clinical Pathology Department, Faculty of Medicine, Alexandria University, Egypt
  • Dalia Abdel Moety Elneely M.D. Clinical Pathology Department, Faculty of Medicine, Alexandria University, Egypt
  • Ahmed Abdel Rahman M.D. Haematology Department, Faculty of Medicine, Alexandria University, Egypt
  • Asmaa El Sayed El Araby Hassan Ali Agram MBBCh. Clinical Pathology Department, Faculty of Medicine, Alexandria University, Egypt. And Alexandria Fever Hospital- Egypt

DOI:

https://doi.org/10.53555/hsn.v2i8.266

Keywords:

Survivin gene expression, Acute Myeloid Leukemia

Abstract

Background: Acute myeloid leukemia (AML) is a genetically heterogeneous disease characterized by malignant clonal proliferation of immature myeloid cells. Survivin is a member of the inhibitor of apoptosis proteins (IAPs) gene family. It was found that knockdown of survivin was reported to induce apoptosis in leukemia cell lines and also potentiated the chemotherapeutic antileukemic effects.
Aim: Investigating survivin gene expression levels in de novo acute myeloid leukemia at the time of diagnosis, and the correlation between survivin expression at time of diagnosis and the achievement of complete remission after induction chemotherapy. Materials and Methods: Real time quantitative polymerase chain reaction (PCR) was used and the results were evaluated with comparative Ct method for 35 AML cases controlled by 15 non AML patient. Results: The present study showed that Survivin expression was significantly higher in cases than in controls (p<0.001). The mean expression level of survivin among patients with complete remission (28.64 ± 6.23) was significantly lower than those with induction failure (186.86 ± 229.71) (p<0.001). None of AML cases with high expression of Survivin above the median achieved complete remission. The age of AML cases positively correlated to survivin gene expression (r= 0.615, p <0.001). Conclusion: Survivin expression analysis at time of diagnosis may aid in determining the prognosis of AML cases.

Downloads

Download data is not yet available.

References

Saultz JN, Garzon R. Acute Myeloid Leukemia: A Concise Review. Journal of clinical medicine. 2016 Mar 5;5(3):33.

Ferrara F, Schiffer CA. Acute myeloid Leukemia in adults.The Lancet.2013;381(9865):484–495.

O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Goorha S, Lancet J. Acute myeloid leukemia. Journal of the National Comprehensive Cancer Network. 2012 Aug 1;10(8):984-1021.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: a cancer journal for clinicians. 2015 Jan 1;65(1):5-29.

Howlader N, Noone A, Krapcho M, Garshell J, Neyman N, Altekruse S. SEER stat fact sheets: acute myeloid leukemia. 2013. http://seer. cancer. gov/csr. 2013.

Khorshid, O., Diaa, A., El Moaty, M.A., El Fatah, R.A., El Dessouki, I., El Hamid, M.A., El Noshokaty, E., El Saied, G., Fouad, T.M. and Ramadan, S.M., 2011. Clinical features and treatment outcome of acute promyelocytic leukemia patients treated at cairo national cancer institute in Egypt.Mediterranean journal of hematology and infectious diseases,3(1).

Neame PB, Soamboonsrup P, Browman GP, Meyer RM, Benger A, Wilson WE, et al. Classifying acute leukemia by immunophenotyping: a combined FAB-immunologic classification of AML. Blood 1986; 68: 1355-62.

Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114(5): 937-51.

Bacârea A. Diagnosis of Acute Myeloid Leukaemia. Bone. 2012; 10(70.7):78-

Abeloff MD, Armitage JO, NiederhuberJE, Kastan MB, McKenna WG. Abeloff's clinical oncology. Philadelphia: Churchill Livingstone; 2008.

Naeim F, Rao PN, Grody WW. The neoplasms of precursor lymphoblasts. In; Grody WW, Rao PN, Naeim F, editors. Hematopathology: morphology, immunophenotype, cytogenetics and molecular approaches. 1st ed. USA: Elsevier Academic Press: 2008. 257-78.

Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010 Jan 21;115(3):453-74.

Orazi A. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes,and myelodysplastic/myeloproliferative diseases. Pathobiology. 2007 Jun 25;74(2):97-114.

Roy K, Kanwar RK, Krishnakumar S, Cheung CH, Kanwar JR. Competitive inhibition of survivin using a cell-permeable recombinant protein induces cancer-specific apoptosis in colon cancer model. International journal of nanomedicine. 2015;10:1019.

Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T, Altieri DC. Therapeutic Targeting of the Survivin Pathway in Cancer Initiation of Mitochondrial Apoptosis and Suppression ofTumor-associated Angiogenesis. Clinical Cancer Research. 2003 Jul 1;9(7):2683-92.

Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nature reviews Molecular cell biology. 2002 Jun 1;3(6):401-10.

Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nature Reviews Cancer. 2008 Jan 1;8(1):61-70.

Shen C, Liu W, Buck AK, Reske SN. Pro-apoptosis and anti-proliferation effects of a recombinant dominant-negative survivin-T34A in human cancer cells. Anticancer research. 2009 Apr 1;29(4):1423-8.

Sadek H, Ragab S, Rasmy H, Guindy NM, Ezzat W, Hamed M. Expression of the antiapoptotic gene survivin in acute leukemias. J Am Sci. 2010;6(10):1272-82.

Troeger A, Siepermann M, Escherich G, Meisel R, Willers R, GudowiusS, Moritz T, Laws HJ, Hanenberg H, Goebel U, Janka-Schaub GE. Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Haematologica. 2007 Aug 1;92(8):1043-50.

Wrzesień-Kuś A, Smolewski P, Sobczak-Pluta A, Wierzbowska A, Robak T. The inhibitor of apoptosis protein family and its antagonists in acute leukemias. Apoptosis. 2004 Nov 1;9(6):705-15.

Fulda S. Inhibitor of apoptosis proteins in pediatric leukemia: molecular pathways and novel approaches to therapy. Frontiers in oncology. 2014 Jan 27;4:3.

Barbara J Bain,S. Mitchell Lewis, and Imelda Bates. Basic haematological techniques. In: Lewis SM, Bain BJ, Bates I (eds). Dacie and Lewis Practical Haematology.10thed. Germany 2006; 10:25-57.

Bates I. Bone marrow biopsy.In Lewis SM, Bain BJ, Bates I (eds).Dacie and Lewis practical hematology. 10thed. Germany: EI Selvier Ltd. 2006;10:116-24.

Burits h, ashwood r. teitz fudamentals of clinical chemistry, 4th ed. philadelphia: saunders wb, 1996; 82-5.

Bain B, BatesI, Laffan MA, Lewis S. Immunophenotyping. In: Matutes E, Morilla R, Morilla AM (eds). Dacie and lewis practical hamatology. 11th ed. Germany: Elsevier Ltd; 2011. 353-62.

Briggs C, Bain B. Basic hematological techniques. Dacie and lewis practical hamatology. 11th ed Philadelphia, PA:Churchill Living stone/Elsevier Ltd; 2012; 33-49.

Bartlett JM, Stirling D, editors. PCR Protocols. 2nd ed. USA: Humana press Methods in Molecular Biology 2003; 226.

Ibrahim AM, Mansour IM, Wilson MM, Mokhtar DA, Helal AM, Al Wakeel HM. Study of Survivin and X-Linked Inhibitor of Apoptosis Protein (XIAP) Genes in Acute Myeloid Leukemia (AML). Lab Hematol 2012; 18(1):1-10.

OtoOA, PaydasS, TanriverdiK, SeydaogluG, YavuzS, DiselU. Survivin and EPR-1 expression in acute leukemias: Prognostic significance and review of the literature. Leuk Res 2007; 31(11):1495-501.

Mittal P, Meehan KR. The acute leukemias. Hospital Physician. 2001 May;5:37-44.

Padró T, Ruiz S, Bieker R, Bürger H, Steins M, Kienast J, Büchner T, Berdel WE, Mesters RM. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2000 Apr 15;95(8):2637-44.

Sugahara K, Uemura A, Harasawa H, Nagai H, Hirakata Y, Tomonaga M, Murata K, Sohda H, Nakagoe T, Shibasaki SI, Yamada Y. Clinical relevance of survivin as a biomarker in neoplasms, especially in adult T-cell leukemias and acute leukemias. International journal of hematology. 2004 Jul 1;80(1):52-8.

Sadek H, Ragab S, Rasmy H, Guindy NM, Ezzat W, Hamed M. Expression of the antiapoptotic gene survivin in acute leukemias. J Am Sci. 2010;6(10):1272-82.

Raslan H, Heikel A. Expression of the putative tumor suppressor gene gravin and ß actin in acute leukaemias: clinical importance and prognostic value by real-time quantitative PCR. Med J Cairo Univ. 2009;77:57–67.

Azzazi M, El-Arab SE, Hegab HM, Elsalakawy W, Ibrahim R, Shazly M. Prognostic significance of intracellular survivin in myeloid blast cells as an inhibitor of apoptosis in Egyptian adult acute myeloid leukemia patients. The Egyptian Journal of Haematology. 2015 Oct 1;40(4):166.

Sun Y, Gallagher-Jones M, Barker C, Wright GJ. A benchmarked protein microarray-based platform for the identification of novel low-affinity extracellular protein interactions. Analytical biochemistry. 2012 May 1;424(1):45-53.

Zhu K, Qin H, Cha SC, Neelapu SS, Overwijk W, Lizee GA, Abbruzzese JL, Hwu P, Radvanyi L, Kwak LW, Chang DZ. Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. Vaccine. 2007 Nov 14;25(46):7955-61.

Mori A, Wada H, Nishimura Y, Okamoto T, Takemoto Y, Kakishita E. Expression of the antiapoptosis gene survivin in human leukemia. International journal ofhematology. 2002 Feb 1;75(2):161-5.

Adida C, Recher C, Raffoux E, Daniel MT, Taksin AL, Rousselot P, Sigaux F, Degos L, Altieri DC, Dombret H. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. British journal of haematology. 2000 Oct 1;111(1):196-203.

Netterwald J. Survival protein predicts poor prognosis in AML patients [abstract]. Chemother Advisor 2012. http://www.cancertherapyadvisor. com/hematologic-cancers/survival-protein-predicts-poor-prognosis-inaml-patients/article/249510/ [Last accessed on 2015 Oct 13].

Downloads

Published

2016-08-31

How to Cite

Abbassy, H. A., Elneely, D. A. M., Rahman, A. A., & Ali Agram, A. E. S. E. A. H. (2016). Study of the Expression Levels of Survivin Gene in Patients with Acute Myeloid Leukemia. International Journal For Research In Health Sciences And Nursing, 2(8), 01–13. https://doi.org/10.53555/hsn.v2i8.266

Issue

Vol. 2 No. 8 (2016): International Journal For Research In Health Sciences And Nursing

Section

Articles

License

Copyright (c) 2016 gnpublication@

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

In consideration of the journal, Green Publication taking action in reviewing and editing our manuscript, the authors undersigned hereby transfer, assign, or otherwise convey all copyright ownership to the Editorial Office of the Green Publication in the event that such work is published in the journal. Such conveyance covers any product that may derive from the published journal, whether print or electronic. Green Publication shall have the right to register copyright to the Article in its name as claimant, whether separately
or as part of the journal issue or other medium in which the Article is included.

By signing this Agreement, the author(s), and in the case of a Work Made For Hire, the employer, jointly and severally represent and warrant that the Article is original with the author(s) and does not infringe any copyright or violate any other right of any third parties, and that the Article has not been published elsewhere, and is not being considered for publication elsewhere in any form, except as provided herein. Each author’s signature should appear below. The signing author(s) (and, in